Expanded Access Intermediate-Size Patient Population Protocol
Latest Information Update: 15 Feb 2024
Price :
$35 *
At a glance
- Drugs Ensartinib (Primary)
- Indications Non-small cell lung cancer
- Focus Expanded access; First in man; Therapeutic Use
- Sponsors Xcovery Holdings
- 05 Nov 2019 New trial record